Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target

Nuclear factor-κB (NF-κB) activity affects cell survival and determines the sensitivity of cancer cells to cytotoxic agents as well as to ionizing radiation. Preventing the protective function of NF-κB may result in chemo- and radio-sensitization of cancer cells. Therefore, NF-κB has emerged as one...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 1999, Vol.57 (1), p.9-17
Main Authors: Waddick, Kevin G., Uckun, Fatih M.
Format: Article
Language:English
Subjects:
Antineoplastic agents
apoptosis
Biological and medical sciences
cancer
General aspects
Medical sciences
molecular target
Pharmacology. Drug treatments
rational drug design
signal transduction
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 17
container_issue 1
container_start_page 9
container_title Biochemical pharmacology
container_volume 57
creator Waddick, Kevin G.
Uckun, Fatih M.
description Nuclear factor-κB (NF-κB) activity affects cell survival and determines the sensitivity of cancer cells to cytotoxic agents as well as to ionizing radiation. Preventing the protective function of NF-κB may result in chemo- and radio-sensitization of cancer cells. Therefore, NF-κB has emerged as one of the most promising molecular targets in rational drug design efforts of translational cancer research programs.
doi_str_mv 10.1016/S0006-2952(98)00224-X
format article
fullrecord <record><control><sourceid>elsevier_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_1669863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000629529800224X</els_id><sourcerecordid>S000629529800224X</sourcerecordid><originalsourceid>FETCH-LOGICAL-e238t-ab5f53b7fce54c890312524f429600432af868b6349e4b50d421ea0ce27701ce3</originalsourceid><addsrcrecordid>eNo9kM1Kw0AUhQdRsFYfQZiFi3aROj_JZOJGtFgNFF2o0N1wM70pkfyUmWnBV_MhfCaTKq4O9_LdyzmHkEvOZpxxdf3KGFORyBIxyfSUMSHiaHVERlynsl8rfUxG_8gpOfP-Yxi14iNi87bt9hCqPdLgEEKDbaBb120cNJ7CBqrWB2qhtehuaJ7PaLuzNYKjJdjQuej7655OnheDTin0J7TparS7ukcCuA2Gc3JSQu3x4k_H5H3x8DZ_ipYvj_n8bhmhkDpEUCRlIou0tJjEVmdMcpGIuIz7CIzFUkCplS6UjDOMi4StY8ERmEWRpoxblGNy9ft3C95CXbredOXN1lUNuE_Dlcq0kj12-4th72VfoTPeVtjnW1cObTDrrjKcmaFac6jWDL2ZTJtDtWYlfwBWEW2f</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target</title><source>ScienceDirect Freedom Collection</source><creator>Waddick, Kevin G. ; Uckun, Fatih M.</creator><creatorcontrib>Waddick, Kevin G. ; Uckun, Fatih M.</creatorcontrib><description>Nuclear factor-κB (NF-κB) activity affects cell survival and determines the sensitivity of cancer cells to cytotoxic agents as well as to ionizing radiation. Preventing the protective function of NF-κB may result in chemo- and radio-sensitization of cancer cells. Therefore, NF-κB has emerged as one of the most promising molecular targets in rational drug design efforts of translational cancer research programs.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/S0006-2952(98)00224-X</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antineoplastic agents ; apoptosis ; Biological and medical sciences ; cancer ; General aspects ; Medical sciences ; molecular target ; Pharmacology. Drug treatments ; rational drug design ; signal transduction</subject><ispartof>Biochemical pharmacology, 1999, Vol.57 (1), p.9-17</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1669863$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Waddick, Kevin G.</creatorcontrib><creatorcontrib>Uckun, Fatih M.</creatorcontrib><title>Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target</title><title>Biochemical pharmacology</title><description>Nuclear factor-κB (NF-κB) activity affects cell survival and determines the sensitivity of cancer cells to cytotoxic agents as well as to ionizing radiation. Preventing the protective function of NF-κB may result in chemo- and radio-sensitization of cancer cells. Therefore, NF-κB has emerged as one of the most promising molecular targets in rational drug design efforts of translational cancer research programs.</description><subject>Antineoplastic agents</subject><subject>apoptosis</subject><subject>Biological and medical sciences</subject><subject>cancer</subject><subject>General aspects</subject><subject>Medical sciences</subject><subject>molecular target</subject><subject>Pharmacology. Drug treatments</subject><subject>rational drug design</subject><subject>signal transduction</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNo9kM1Kw0AUhQdRsFYfQZiFi3aROj_JZOJGtFgNFF2o0N1wM70pkfyUmWnBV_MhfCaTKq4O9_LdyzmHkEvOZpxxdf3KGFORyBIxyfSUMSHiaHVERlynsl8rfUxG_8gpOfP-Yxi14iNi87bt9hCqPdLgEEKDbaBb120cNJ7CBqrWB2qhtehuaJ7PaLuzNYKjJdjQuej7655OnheDTin0J7TparS7ukcCuA2Gc3JSQu3x4k_H5H3x8DZ_ipYvj_n8bhmhkDpEUCRlIou0tJjEVmdMcpGIuIz7CIzFUkCplS6UjDOMi4StY8ERmEWRpoxblGNy9ft3C95CXbredOXN1lUNuE_Dlcq0kj12-4th72VfoTPeVtjnW1cObTDrrjKcmaFac6jWDL2ZTJtDtWYlfwBWEW2f</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Waddick, Kevin G.</creator><creator>Uckun, Fatih M.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope></search><sort><creationdate>1999</creationdate><title>Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target</title><author>Waddick, Kevin G. ; Uckun, Fatih M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e238t-ab5f53b7fce54c890312524f429600432af868b6349e4b50d421ea0ce27701ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Antineoplastic agents</topic><topic>apoptosis</topic><topic>Biological and medical sciences</topic><topic>cancer</topic><topic>General aspects</topic><topic>Medical sciences</topic><topic>molecular target</topic><topic>Pharmacology. Drug treatments</topic><topic>rational drug design</topic><topic>signal transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waddick, Kevin G.</creatorcontrib><creatorcontrib>Uckun, Fatih M.</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waddick, Kevin G.</au><au>Uckun, Fatih M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target</atitle><jtitle>Biochemical pharmacology</jtitle><date>1999</date><risdate>1999</risdate><volume>57</volume><issue>1</issue><spage>9</spage><epage>17</epage><pages>9-17</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>Nuclear factor-κB (NF-κB) activity affects cell survival and determines the sensitivity of cancer cells to cytotoxic agents as well as to ionizing radiation. Preventing the protective function of NF-κB may result in chemo- and radio-sensitization of cancer cells. Therefore, NF-κB has emerged as one of the most promising molecular targets in rational drug design efforts of translational cancer research programs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><doi>10.1016/S0006-2952(98)00224-X</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-2952
ispartof Biochemical pharmacology, 1999, Vol.57 (1), p.9-17
issn 0006-2952
1873-2968
language eng
recordid cdi_pascalfrancis_primary_1669863
source ScienceDirect Freedom Collection
subjects Antineoplastic agents
apoptosis
Biological and medical sciences
cancer
General aspects
Medical sciences
molecular target
Pharmacology. Drug treatments
rational drug design
signal transduction
title Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A06%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Innovative%20treatment%20programs%20against%20cancer:%20II.%20nuclear%20factor-%CE%BAB%20(NF-%CE%BAB)%20as%20a%20molecular%20target&rft.jtitle=Biochemical%20pharmacology&rft.au=Waddick,%20Kevin%20G.&rft.date=1999&rft.volume=57&rft.issue=1&rft.spage=9&rft.epage=17&rft.pages=9-17&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/S0006-2952(98)00224-X&rft_dat=%3Celsevier_pasca%3ES000629529800224X%3C/elsevier_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e238t-ab5f53b7fce54c890312524f429600432af868b6349e4b50d421ea0ce27701ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true